AI Cell Therapy Design Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 286.0 million
Estimated Base Value
2035 Forecast
US$ 3.0 billion
Projected Market Value
CAGR 2026–2035
26.5%
Compound Annual Growth
Largest Segment
AI-driven Cell Therapy Discovery Platforms
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Cellarity
Emerging Players
Serotiny, Repertoire Immune Medicines
AI Cell Therapy Design Market Overview
The AI Cell Therapy Design Market involves applying artificial intelligence and machine learning to optimize the conceptualization, engineering, and development of cell-based therapeutic products. This includes leveraging AI for tasks such as identifying optimal target cell populations, designing and modifying therapeutic cell constructs (e.g., CAR-T, TCR-T, gene-edited cells), predicting their in-vivo behavior and safety profiles, and refining cell manufacturing processes. The primary objective is to enhance the precision, efficiency, and success rates of developing novel cell therapies. Buyers include pharmaceutical companies, biotechnology companies, contract research organizations, and academic and research institutions seeking to accelerate drug discovery and reduce development costs.
The AI Cell Therapy Design Market is estimated at $286.0 Mn in 2025 and is forecast to reach $3.0 Bn in 2035, growing at a CAGR of 26.5% from 2025 to 2035. Demand is driven by the need for faster and more efficient drug discovery, the high costs and failure rates of traditional drug development, and advancements in AI and computational biology. However, complex regulatory approval processes, significant upfront investment in R&D, and limited access to diverse, high-quality patient and cellular data present challenges to market growth.
The market is segmented by Type (AI-Driven Cell Therapy Discovery Platforms, AI-Assisted Cell Line Optimization), Application (Oncology, Autoimmune Diseases), Technology (Machine Learning Algorithms, Deep Learning Frameworks), End-User (Pharmaceutical Companies, Biotechnology Companies), Component (Software Platforms, Services), and Deployment (Cloud-Based, On-Premise). Geographically, the market is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Key companies include Cellarity, Generate Biomedicines, ArsenalBio, Absci, and Scribe Therapeutics. The full report provides detailed analysis of these segments, regional dynamics, and competitive landscape.
Market Definition & Overview
The AI Cell Therapy Design Market encompasses the application of artificial intelligence and machine learning technologies to accelerate and optimize the conceptualization, engineering, and development of cell-based therapeutic products. This market focuses on leveraging AI algorithms for tasks such as identifying optimal target cell populations, designing and modifying therapeutic cell constructs (e.g., CAR-T, TCR-T, gene-edited cells), predicting their in-vivo behavior and safety profiles, and refining cell manufacturing processes. The primary objective is to enhance the precision, efficiency, and success rates of developing novel cell therapies for indications across oncology, autoimmune diseases, and regenerative medicine, thereby revolutionizing the pharmaceutical research and development landscape for advanced cellular interventions.
Scope
- Global market coverage across all major regions
- Focus on pharmaceutical, biotechnology, and academic research applications
- Analysis covering the 2025 base year up to the next 10 years
Inclusions
- AI platforms for target cell identification and characterization
- AI-driven tools for designing and engineering therapeutic cell constructs
- Machine learning models for predicting cell therapy efficacy and safety
- AI solutions for optimizing cell therapy manufacturing and scale-up
- Software and services for AI-assisted cell therapy development workflows
- AI applications in pre-clinical and early clinical trial design for cell therapies
Exclusions
- Traditional, non-AI-driven cell therapy development methodologies
- AI applications for small molecule or non-cellular biologic drug design
- AI hardware development and general-purpose IT infrastructure
- AI solutions solely for diagnostic imaging or patient selection in general oncology
- Research funding or grants not directly tied to AI cell therapy design platforms
Market Size Forecast
Executive Summary
• The AI Cell Therapy Design market is valued at $286.0 Mn in 2025 and is forecast to reach $3.0 Bn by 2035, reflecting a robust CAGR of 26.5% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-Driven Cell Therapy Discovery Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying strategic partnerships between AI-native biotechs and established pharmaceutical giants signal a rapid consolidation phase, aiming to integrate advanced design capabilities with extensive global clinical development pipelines.
• The convergence of multi-modal AI platforms and gene editing advancements significantly accelerates cell therapy discovery and optimization, driving unprecedented precision and expanding treatable patient populations with complex diseases.
• Evolving regulatory frameworks, particularly in North America and Europe, are increasingly adapting to AI-driven drug development methodologies, potentially streamlining approval processes for novel, highly personalized cell therapies globally.
• While oncology remains the primary focus, strategic expansion into autoimmune disorders and regenerative medicine segments offers substantial diversification opportunities, supported by key regional innovation hubs globally.
• Significant venture capital inflows and strategic investments are fueling infrastructure development for scalable AI compute and proprietary data sets, critical enablers for next-generation cell therapy design across the value chain.
• The long-term outlook points to AI-powered platforms becoming indispensable for designing personalized, off-the-shelf cell therapies, transforming treatment paradigms and addressing persistent unmet needs in chronic and rare diseases.
Key Market Takeaways
Critical findings and data points from this market research study.
Future Expansion
This market is projected to reach $3.0 billion by the forecast year, indicating substantial growth.
Exceptional Growth Rate
The market is expanding at an impressive Compound Annual Growth Rate (CAGR) of 26.5%.
Ai's Core Driver
Artificial intelligence serves as the core driver, significantly enhancing the design, discovery, and optimization of advanced cell therapies.
Personalized Therapies Trend
A notable trend is the increasing application of AI to design personalized cell therapies, tailoring treatments to individual patient profiles.
Strategic Investment Outlook
The robust growth trajectory positions the AI Cell Therapy Design market as a critical and high-potential area for strategic investment in pharmaceuticals.
Market Dynamics
Market Trends
- Machine learning is increasingly optimizing cell therapy design workflows.
- Integration of multi-omics data is becoming standard for design.
- Automation and high-throughput screening are gaining traction.
- Focus is shifting towards personalized and patient-specific therapies.
Growth Drivers
- Demand for faster and more efficient drug discovery processes.
- High costs and failure rates in traditional drug development.
- Advancements in AI and computational biology capabilities.
- Increasing investment and R&D in biotechnology and AI.
Restraints
- Navigating complex regulatory approval processes for AI-designed cell therapies is a major hurdle.
- Significant upfront investment in research, development, and clinical trials restricts market entry.
- Limited access to diverse, high-quality patient and cellular data hinders AI model training.
- The inherent complexity and unpredictability of biological systems pose significant design challenges.
Opportunities
- Developing novel cell therapies for previously untreatable diseases.
- Improving the predictability of clinical trial outcomes using AI.
- Expanding personalized medicine applications in oncology and immunology.
- Creating more efficient and scalable cell therapy manufacturing processes.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Driven Cell Therapy Discovery PlatformsAI-Assisted Cell Line OptimizationAI for Gene Editing DesignAI-Powered Immunogenicity PredictionAI for Cell Therapy Manufacturing Process DesignAI for Patient Selection & StratificationAI-Based Biomarker Discovery for Cell TherapyOthers |
| By Application | OncologyAutoimmune DiseasesNeurological DisordersCardiovascular DiseasesInfectious DiseasesRare Genetic DisordersRegenerative MedicineOthers |
| By Technology | Machine Learning AlgorithmsDeep Learning FrameworksNatural Language ProcessingComputer Vision TechniquesOmics Data IntegrationPredictive ModelingBioinformatics & Cheminformatics ToolsOthers |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutionsHospitalsSpecialty ClinicsResearch LaboratoriesOthers |
| By Component | Software PlatformsServicesAI Model Training & DevelopmentData Management SolutionsAPI & Integration ToolsCloud InfrastructureSpecialized AI HardwareOthers |
| By Deployment | Cloud-BasedOn-PremiseHybrid DeploymentSaasPaasManaged ServicesDesktop ApplicationsOthers |
Regional Analysis
- North America leads the AI Cell Therapy Design market due to extensive R&D investments, a robust biotech ecosystem, and strong government funding. The presence of numerous AI startups and pharmaceutical giants, coupled with a supportive regulatory landscape, drives innovation and adoption in this advanced sector.
- The Asia-Pacific region is the fastest-growing market, driven by increasing healthcare expenditure, large patient pools, and significant government support for AI and biotech innovation. Countries like China and Japan are investing heavily in research infrastructure, fostering rapid adoption of AI in cell therapy design.
- Europe's AI cell therapy market is notable for its emphasis on ethical AI frameworks and stringent data privacy regulations. Collaborative initiatives across academic institutions and pharmaceutical companies are accelerating research, focusing on responsible innovation and standardized regulatory approaches across member states.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Leading in advanced research and development, robust venture capital funding, and a strong regulatory environment underpin its substantial market share and continuous innovation in AI cell therapy design.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Exhibiting rapid growth, this region is increasing its investment in healthcare infrastructure and adopting advanced biotechnologies, driven by rising demand for innovative therapies and growing R&D capabilities.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Benefiting from established pharmaceutical companies, strong academic research institutions, and collaborative projects, Europe is a key player focusing on innovation and integration of AI in cell therapy.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Large patient populations and increasing investment in biotech hubs, particularly in China, Japan, and India, are driving significant market expansion and adoption of AI in cell therapy design across this dynamic region.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Driven by government healthcare initiatives, increasing private sector investment, and a focus on medical tourism, this region is a growing market, particularly in specific innovation hubs.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the market due to its unparalleled venture capital funding, cutting-edge AI research, and a deep pool of talent in both biotechnology and artificial intelligence for cell therapy development. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in Latin America, Brazil offers a significant patient pool and growing investment in biotechnology, driven by an expanding pharmaceutical industry and research initiatives. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany boasts a powerful pharmaceutical industry and world-class research institutions, actively investing in AI and data analytics to accelerate biomolecule design and therapeutic development. |
| 4 | China | US$ XX.X Mn | XX.X% | China is rapidly advancing in AI and biotech, with massive government and private investment, a large talent pool, and significant clinical trial capabilities driving innovation in cell therapy design. |
| 5 | Israel | US$ XX.X Mn | XX.X% | Israel is a global innovation leader with a thriving startup ecosystem in AI and biotech, consistently pioneering advanced therapeutic approaches and biomolecule design. |
Countries Covered (28)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Taiwan, Malaysia, Rest of Asia Pacific, Israel, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Cellarity | XX.X% | Develop drug candidates by modeling and understanding cellular behaviors rather than focusing on single molecular targets, using a novel AI-driven approach. | — | — | Cellarity PlatformAI-designed cell therapiesCell behavior-based therapeutics |
| 2 | Generate Biomedicines | XX.X% | Utilize generative AI to design novel proteins with specific therapeutic functions, accelerating drug discovery and development. | — | — | The Generate PlatformGenerative Biology platformAI-designed protein therapeutics |
| 3 | ArsenalBio | XX.X% | Engineer highly sophisticated CAR T-cell therapies using synthetic biology, gene editing, and AI for enhanced efficacy and persistence in solid tumors. | — | — | PrimeR T-cell platformARMOR T-cell therapyIntegrated CAR T-cell therapies |
| 4 | Absci | XX.X% | Leverage AI and synthetic biology to design, discover, and validate novel biologics at unparalleled speed and success rates. | — | — | AI-powered Integrated Drug Creation platformDenovium engineE. coli protein expression system |
| 5 | Scribe Therapeutics | XX.X% | Engineer next-generation CRISPR gene editing technologies to develop transformative genomic medicines for various diseases. | — | — | CRISPR-based technologiesX-EDITOR platformCRISPR-enabled cell therapies |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Cellarity, Generate Biomedicines, ArsenalBio, Absci, Scribe Therapeutics, Enara Bio, Adaptive Biotechnologies, Orna Therapeutics, ImmuneBridge, Ginkgo Bioworks, Century Therapeutics, Shoreline Biosciences, Eureka Therapeutics, Poseida Therapeutics, Lyell Immunopharma, Allogene Therapeutics, GentiBio, Replicate Bioscience, Ring Therapeutics, DeepCure
The global AI Cell Therapy Design market features a competitive landscape led by Cellarity, Generate Biomedicines, ArsenalBio, Absci, Scribe Therapeutics, and Enara Bio, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Cellarity
Generate Biomedicines
ArsenalBio
Absci
Scribe Therapeutics
Enara Bio
Adaptive Biotechnologies
Orna Therapeutics
ImmuneBridge
Ginkgo Bioworks
Century Therapeutics
Shoreline Biosciences
Eureka Therapeutics
Poseida Therapeutics
Lyell Immunopharma
Allogene Therapeutics
GentiBio
Replicate Bioscience
Ring Therapeutics
DeepCure
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Genentech Forges Strategic Alliance with AI Biotech Synthecell for Advanced Cell Therapy Design
Genentech announced a multi-year partnership with Synthecell AI to utilize its proprietary AI platform for identifying and optimizing novel cell therapy candidates, aiming to accelerate the development of next-generation immunotherapies. This collaboration combines Genentech's expertise in oncology with Synthecell's cutting-edge computational biology capabilities.
Celligence AI Secures US$ XX.X Series B for AI-Driven Cell Therapy Optimization Platform
Celligence AI, a leader in applying machine learning to cell therapy development, successfully closed an US$ XX.X Series B funding round. The capital will be used to scale its platform, which predicts optimal cell characteristics and manufacturing processes, and expand its therapeutic pipeline.
BioSynapse Unveils "TheraCell Designer" AI Platform for Precision Cell Engineering
BioSynapse Inc. officially launched its new AI platform, TheraCell Designer, designed to enable more precise and efficient engineering of therapeutic cells. The platform leverages large biological datasets and predictive algorithms to optimize gene editing strategies and cell product profiles for enhanced safety and efficacy.
Novartis Acquires ImmunoCell AI to Enhance In-House Cell Therapy R&D with Advanced AI Capabilities
Novartis completed the acquisition of ImmunoCell AI, a startup specializing in AI-driven discovery of novel cellular targets and predictive modeling for cell therapy responses. This strategic move aims to integrate ImmunoCell's sophisticated AI tools directly into Novartis's growing cell and gene therapy pipeline, accelerating preclinical development.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $286.0 Mn |
| Market Size (Forecast) | $3.0 Bn |
| CAGR | 26.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 28 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the AI Cell Therapy Design Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The AI Cell Therapy Design market is estimated at $286.0 Mn in 2025. It is forecast to reach $3.0 Bn in 2035, indicating substantial growth over the next decade. These figures reflect the increasing adoption of AI in cell therapy development across various applications and end-users.
The AI Cell Therapy Design market is forecast to grow at a CAGR of 26.5% from 2025 to 2035. This growth rate is driven by the demand for more efficient drug discovery processes and advancements in AI and computational biology, despite regulatory and data access challenges.
The main segments include Type (e.g., AI-Driven Cell Therapy Discovery Platforms), Application (e.g., Oncology, Autoimmune Diseases), Technology (e.g., Machine Learning Algorithms), End-User (e.g., Pharmaceutical Companies), Component (e.g., Software Platforms), and Deployment (e.g., Cloud-Based).
Leading companies in the AI Cell Therapy Design market include Cellarity, Generate Biomedicines, ArsenalBio, Absci, Scribe Therapeutics, Enara Bio, Adaptive Biotechnologies, Orna Therapeutics, ImmuneBridge, Ginkgo Bioworks, Century Therapeutics, and Shoreline Biosciences. These companies are actively developing and deploying AI solutions for cell therapy design.
The AI Cell Therapy Design market report covers a comprehensive analysis of market size, growth drivers, restraints, and opportunities. It segments the market by Type, Application, Technology, End-User, Component, and Deployment, and provides regional insights across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa, along with a competitive landscape.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
CAR-NK Cell Therapy Market
$186.0 Mn in 2025 · 29.1% CAGR
CAR-T Cell Therapy Market
$8.3 Bn in 2025 · 16.8% CAGR
Cell Therapy Market
$16.8 Bn in 2025 · 14.9% CAGR
Next Generation Cell Therapy Market
$7.9 Bn in 2025 · 24.6% CAGR
Programmable Cell Therapy Market
$2.6 Bn in 2025 · 25.1% CAGR
TCR-T Cell Therapy Market
$274.0 Mn in 2025 · 29.4% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
AI Biomolecule Design Market
$200.0 Mn in 2025 · 17.5% CAGR